Latest Breaking News On - Arranz arija - Page 1 : comparemela.com

ASCO 2024: Optimal Treatment Intensity for Frontline Therapy for Advanced Urothelial Cancer: Which Regimen for Which Patient?

ASCO 2024 optimal treatment intensity for frontline therapy for advanced urothelial cancer, gemcitabine + cisplatin, advanced urothelial cancer, metastatic urothelial carcinoma.

United statesFox chase cancer centerArranz arijaPooja ghataliaZachary klaassenAmerican society of clinical oncologyGeorgia cancer centerClinical oncologyUrologic oncologistAssociate professorAnnual meetingMaintenance therapyMetastatic urothelialAdvanced urothelial

ESMO 2023: Discussant: EV-302/KEYNOTE-A39 & CheckMate 901: Welcoming a New Standard of Care in the First-Line Treatment of Urothelial Carcinoma

ESMO 2023: Discussant: EV-302/KEYNOTE-A39 & CheckMate 901: Welcoming a New Standard of Care in the First-Line Treatment of Urothelial Carcinoma
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Enfortumab vedotinArranz arijaCancer researchSociety of urologic oncologyUniversity of torontoBladder cancer section genitourinary malignancies branch centerEuropean society of medical oncologyNational cancer instituteMedical oncologyAnnual congressAndrea apoloRandomized phaseUrologic oncologyClinical fellowAnnual meetingMaintenance therapy

Exploratory IMvigor130 Data Support Single-agent Atezolizumab in Select Patients With Urothelial Carcinoma

Aristotelis Bamias, MD, discusses the efficacy and safety data from the final OS analysis of the IMvigor130 trial and emphasizes the clinical implications of this research in metastatic urothelial cancer.

United statesBristol myers squibbAstellas pharmaArranz arijaAristotelis bamiasDebiopharm groupUniversity of athensNational comprehensive cancer networkMedical schoolPatients with locally advanced or metastatic urothelial carcinomaAtezolizumab monotherapyImvigor130 trial